Beyond the established SUD agents — naltrexone, acamprosate, disulfiram for AUD; buprenorphine, methadone, naltrexone for OUD; varenicline, bupropion, NRT for smoking — several anticonvulsants have accumulated off-label evidence for substance use disorders. Topiramate and gabapentin are the most clinically relevant.
- Class
- Off-label and adjunctive SUD pharmacotherapy
- Mechanism
- Topiramate: GABAergic, glutamate (AMPA/kainate) modulation, carbonic anhydrase inhibition. Gabapentin: voltage-gated calcium channel modulation. Each may reduce craving across multiple SUDs.
- Typical dose
- Topiramate 50-300 mg/day. Gabapentin 600-1800 mg/day in divided doses.
- FDA indications
- Off-label SUD treatment (AUD, stimulant UD, cannabis withdrawal)
- Key adverse effects
- Topiramate: cognitive dulling ("dopamax"), paresthesias, weight loss, metabolic acidosis, kidney stones. Gabapentin: sedation, ataxia, edema, abuse potential (especially with opioids).
- Representative agents
- Topiramate (AUD off-label, stimulant UD), gabapentin (AUD off-label, cannabis withdrawal), baclofen (AUD off-label, particularly in cirrhosis)
These agents have evolving evidence for SUDs. Topiramate has moderate evidence for AUD (reduces heavy drinking) and stimulant use disorder. Gabapentin shows some efficacy for AUD and cannabis withdrawal but has its own abuse potential. Niche use — combined with established treatments.
Topiramate for alcohol use disorder has moderate evidence supporting reduced heavy drinking days. The mechanism is multi-target — GABA enhancement, glutamate (AMPA/kainate) modulation, carbonic anhydrase inhibition — distinct from naltrexone or acamprosate. For the patient who has failed first-line agents or who specifically benefits from topiramate's profile (e.g., comorbid migraine where topiramate prophylaxis is also indicated), topiramate is a reasonable second-line choice. Cognitive dulling ("dopamax" — word-finding difficulty, slowed processing) is the main tolerability constraint, particularly at higher doses. Start low, titrate slowly.
Topiramate, gabapentin, and other adjunctive agents address substance use disorders through anticonvulsant and neuromodulatory mechanisms repurposed for craving and withdrawal.
Mechanism note: Topiramate, gabapentin, and similar agents are evidence-informed adjuncts — they address craving, anxiety, and protracted-withdrawal symptoms that first-line SUD medications leave uncovered.
Gabapentin has some evidence for both AUD and cannabis withdrawal. The mechanism is voltage-gated calcium channel modulation. The clinical signal is real but the effect size is modest. The major concern is abuse potential — gabapentin is itself misused, particularly when combined with opioids. PDMP screen, careful patient selection, particularly cautious co-prescription with opioids.
Baclofen — GABA-B agonist — has accumulated evidence for AUD, particularly in cirrhotic patients where its hepatic safety profile is favorable. Used more in European practice than US.
These adjunctive agents share a clinical position: useful when first-line agents have failed or specific patient factors favor them. Topiramate for the AUD patient with migraine. Gabapentin for AUD with anxiety and pain (with abuse-potential caution). Baclofen for AUD with cirrhosis.
- Cost
- Topiramate generic ~$10-30/month. Gabapentin generic ~$5-25/month.
- Generic status
- Both generic for years.
- Formulary typical
- Tier 1 generics.
- Access friction
- Off-label use — not always covered for SUD indications. Document primary diagnosis carefully.
Prescriber tip: For AUD off-label topiramate, code primary diagnosis as AUD and document rationale. Counsel cognitive effects upfront. Gabapentin abuse potential with opioids is the safety concern.
Match the agent to the patient. Behavioral treatment and mutual-help support remain foundational regardless of pharmacologic choice.